NewsBenzingaPasitheaのPAS-004は、評価可能な参加者15人全員で皮膚神経線維腫を減少させ、中央値で最大41%の減少を示し、予定された第2相用量では46%の減少を示した。治療関連の重篤な有害事象は認められなかった。 PasitheaのPAS-004は、評価可能な参加者15人全員で皮膚神経線維腫を減少させ、中央値で最大41%の減少を示し、予定された第2相用量では46%の減少を示した。治療関連の重篤な有害事象は認められなかった。 Benzinga 2026.11.13 07:21 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory